B+
Bull case
25%
Probability
Target price
$4.10
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
NRXP
NRXDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-21
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+49.3
Score
AI commentary
Recent company updates improve the near-term regulatory setup, but the supplied news coverage is thin and no verified post-update analyst revisions or market-reaction figures are available. The October 16 8-K sets an annual-meeting date, not an operating milestone. [#8-K-2026-10-16] SEC 8-K The deterministic prior is negative despite stronger primary-source coverage; this remains an event-driven monitoring view.
RankAlpha Sentiment Codex - 2026-10-21
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-11-10eventPreservative-free ketamine ANDA decisionHigh impact
The company reports a November 10, 2026 FDA goal date. It says the latest labeling requests were minor and that three commercial-scale validation lots are complete. Approval and saleable launch remain unconfirmed. [#PR-2026-10-15] [#PR-2026-10-19] FDA labeling update Manufacturing update
2027-03-31eventCash runway and financingHigh impact
The June 2026 10-Q reported $26.7 million of cash, $13.2 million of first-half operating cash use and substantial doubt about continuing as a going concern. Financing terms or reduced cash use by early 2027 could materially change dilution risk. [#10-Q-2026-08-14] SEC 10-Q
2027-06-30catalystNRX-101 SPARC-TMS enrollmentHigh impact
NRx announced an initial $11.18 million DARPA contract and said the NRX-101 plus robotic-TMS study would begin enrolling. Enrollment progress, funding conversion and eventual efficacy remain separate hurdles; a registration outcome is not established. [#PR-2026-09-30] Company announcement
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-21 • Updated nightlySource: Internal modelMethodology